Rhenman & Partners Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-325,000
| Closed | -$19.8M | – | 95 |
|
|
2025
Q1 | $19.8M | Buy |
+325,000
| New | +$18.9M | 2.28% | 16 |
|
|
2021
Q4 | – | Sell |
-125,000
| Closed | -$7.4M | – | 93 |
|
|
2021
Q3 | $7.4M | Hold |
125,000
| – | – | 0.52% | 59 |
|
|
2021
Q2 | $8.35M | Sell |
125,000
-200,000
| -62% | -$13M | 0.57% | 60 |
|
|
2021
Q1 | $20.5M | Sell |
325,000
-15,000
| -4% | -$933K | 1.43% | 31 |
|
|
2020
Q4 | $21.1M | Buy |
340,000
+50,000
| +17% | +$3.07M | 1.72% | 20 |
|
|
2020
Q3 | $17.5M | Sell |
290,000
-90,000
| -24% | -$5.42M | 1.55% | 26 |
|
|
2020
Q2 | $22.3M | Buy |
380,000
+30,000
| +9% | +$1.79M | 2.41% | 6 |
|
|
2020
Q1 | $19.5M | Buy |
350,000
+10,000
| +3% | +$611K | 2.73% | 6 |
|
|
2019
Q4 | $21.8M | Sell |
340,000
-75,000
| -18% | -$4.3M | 2.39% | 7 |
|
|
2019
Q3 | $21M | Buy |
415,000
+76,614
| +23% | +$3.6M | 2.64% | 8 |
|
|
2019
Q2 | $15.3M | Buy |
338,386
+108,386
| +47% | +$5.05M | 1.69% | 25 |
|
|
2019
Q1 | $11M | Sell |
230,000
-140,000
| -38% | -$6.97M | 1.28% | 31 |
|
|
2018
Q4 | $19.2M | Buy |
370,000
+40,000
| +12% | +$2.15M | 2.2% | 12 |
|
|
2018
Q3 | $20.5M | Sell |
330,000
-110,000
| -25% | -$6.53M | 2.05% | 15 |
|
|
2018
Q2 | $24.4M | Buy |
440,000
+90,000
| +26% | +$4.86M | 2.49% | 6 |
|
|
2018
Q1 | $22.1M | Buy |
350,000
+220,198
| +170% | +$14.2M | 2.73% | 7 |
|
|
2017
Q4 | $7.95M | Sell |
129,802
-30,700
| -19% | -$1.92M | 1.07% | 35 |
|
|
2017
Q3 | $10.2M | Buy |
160,502
+46,907
| +41% | +$2.74M | 1.31% | 28 |
|
|
2017
Q2 | $6.33M | Sell |
113,595
-87,405
| -43% | -$4.76M | 0.91% | 41 |
|
|
2017
Q1 | $10.9M | Sell |
201,000
-80,000
| -28% | -$4.39M | 1.73% | 21 |
|
|
2016
Q4 | $16.4M | Buy |
281,000
+44,000
| +19% | +$2.41M | 3.15% | 2 |
|
|
2016
Q3 | $12.8M | Buy |
237,000
+100,000
| +73% | +$6.42M | 2.03% | 14 |
|
|
2016
Q2 | $10.1M | Sell |
137,000
-5,000
| -4% | -$353K | 1.79% | 17 |
|
|
2016
Q1 | $9.07M | Sell |
142,000
-41,000
| -22% | -$2.59M | 1.8% | 17 |
|
|
2015
Q4 | $12.6M | Sell |
183,000
-9,000
| -5% | -$595K | 1.9% | 12 |
|
|
2015
Q3 | $11.4M | Sell |
192,000
-6,000
| -3% | -$381K | 1.81% | 21 |
|
|
2015
Q2 | $13.2M | Buy |
198,000
+69,000
| +53% | +$4.55M | 1.58% | 16 |
|
|
2015
Q1 | $8.32M | Buy |
129,000
+14,000
| +12% | +$876K | 1.4% | 26 |
|
|
2014
Q4 | $6.79M | Buy |
115,000
+16,000
| +16% | +$902K | 1.97% | 11 |
|
|
2014
Q3 | $5.07M | Buy |
99,000
+14,000
| +16% | +$699K | 1.48% | 20 |
|
|
2014
Q2 | $4.12M | Sell |
85,000
-1,815
| -2% | -$89.4K | 1.22% | 22 |
|
|
2014
Q1 | $3.18M | Buy |
86,815
+14,815
| +21% | +$788K | 0.95% | 37 |
|
|
2013
Q4 | $3.83M | Buy |
+72,000
| New | +$3.67M | 1.5% | 21 |
|
Other funds holding BMY
Rhenman & Partners Asset Management's BMY Position: Q2 2025 in Review
Rhenman & Partners Asset Management sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 325,000 shares — an estimated $19.8M sold.
Rhenman & Partners Asset Management first reported a position in BMY in Q4 2013 and held it in 33 quarters. The position peaked at $24.4M in Q2 2018. 2,293 funds tracked by Wall St. Rank hold BMY as of Q2 2025.
- Rhenman & Partners Asset Management reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
- Rhenman & Partners Asset Management sold 325,000 Bristol-Myers Squibb shares in Q2 2025, an estimated $19.8M.
- Rhenman & Partners Asset Management first reported a position in Bristol-Myers Squibb in Q4 2013 and held it in 33 quarters.
- Rhenman & Partners Asset Management's Bristol-Myers Squibb position peaked at $24.4M in Q2 2018.
- 2,293 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.
Based on Rhenman & Partners Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.